Max Healthcare Institute Limited traded at 1,081.00 this Friday November 20th, increasing 40.35 or 3.88 percent since the previous trading session. Looking back, over the last four weeks, Max Healthcare Institute Limited gained 31.85 percent. Over the last 12 months, its price fell by 8.48 percent. Looking ahead, we forecast Max Healthcare Institute Limited to be priced at 923.99 by the end of this quarter and at 857.99 in one year, according to Trading Economics global macro models projections and analysts expectations.
Max Healthcare Institute Limited is an India-based integrated healthcare provider. The Company offers an integrated suite of diagnostics and lab services, ambulatory care, consultations, surgical and non-surgical procedures, and medical treatment. Its clinical offerings span a range of therapeutic areas, including radiation therapy for cancer, and specialized treatments in oncology, neurosciences, cardiac sciences, orthopedics, renal and liver care and minimally invasive surgery. It also provides consultations across diverse medical specialties such as diabetes and endocrinology, pulmonology, nephrology, dermatology, gastroenterology, physiotherapy and rehabilitation. It also caters to specific healthcare needs, including transplant services, audiology and speech therapy, and dedicated pediatric care. It offers a home care program through Max@Home, enabling patients to receive medical attention in the comfort of their homes. Its Max Lab provides at-home diagnostic testing.